Alnylam Pharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- Alnylam Pharmaceuticals's estimated annual revenue is currently $749.3M per year.
- Alnylam Pharmaceuticals received $445.6M in venture funding in January 2019.
- Alnylam Pharmaceuticals's estimated revenue per employee is $267,898
- Alnylam Pharmaceuticals's total funding is $3B.
- Alnylam Pharmaceuticals's current valuation is $17.8B. (January 2022)
Employee Data
- Alnylam Pharmaceuticals has 2797 Employees.
- Alnylam Pharmaceuticals grew their employee count by 7% last year.
Alnylam Pharmaceuticals's People
Name | Title | Email/Phone |
---|---|---|
1 | CMO Management Drug Product Team Co-op | Reveal Email/Phone |
2 | Chief Accounting Officer | Reveal Email/Phone |
3 | CEO | Reveal Email/Phone |
4 | Sr. Executive Assistant to the Chief Financial Officer | Reveal Email/Phone |
5 | Senior Manager, CMO Management | Reveal Email/Phone |
6 | Executive Assistant to VP, General Manager UK & Irl | Reveal Email/Phone |
7 | Chief Staff to the Chief Commercial Officer | Reveal Email/Phone |
8 | SVP, Chief Patent Counsel | Reveal Email/Phone |
9 | VP, Investor Relations & Corporate Communications | Reveal Email/Phone |
10 | SVP | Reveal Email/Phone |
Alnylam Pharmaceuticals Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 2 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 6 | 0% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | $5.4M | 35 | 3% | N/A | N/A |
#10 | $1.6M | 10 | 0% | N/A | N/A |
What Is Alnylam Pharmaceuticals?
To those who say impossible, impractical, unrealistic, we say: CHALLENGE ACCEPTED. We are developing an innovative, entirely new class of medicines called RNAi therapeutics to treat rare genetic, cardio metabolic, acute hepatic infectious and central nervous system (CNS) diseases. Alnylam was founded in 2002 based on a Nobel Prize-winning breakthrough in biology - the discovery of RNA interference (RNAi), and a bold vision that this discovery could be used to silence disease-causing genes upstream of today's medicines. We are relentless in our pursuit of new treatments because we believe that RNAi therapeutics can be used to treat many diseases for which treatment options do not exist or are inadequate. Overall, we believe that patients shouldn't have to wait for hope. Alnylam is turning scientific possibility into reality - in August of 2018, the U.S. FDA approval of our first product ONPATTRO (patisiran) which is also the first-ever approved RNAi therapeutic. Our robust RNAi discovery platform and deep pipeline of investigational medicines includes three programs in late-stage clinical development and multiple programs in early-stage clinical development. We are a global and diverse company of more than 850 people. We pride ourself on fostering a fun, inclusive and dynamic work environment where employees can recognize their fullest potential. That's why we've been named a Boston Globe Top Place to Work three years in a row! We are based in Cambridge, U.S., with offices in Zug, Switzerland, and Maidenhead, UK, and operations and employees across the U.S. and throughout Europe and Asia. We invite you to connect with us by following us on LinkedIn, Twitter (@Alnylam) and YouTube. You can also sign up for email updates here: http://www.alnylam.com/signup-for-updates/
keywords:Biotechnology,Healthcare,Pharmaceuticals$3B
Total Funding
2797
Number of Employees
$749.3M
Revenue (est)
7%
Employee Growth %
$17.8B
Valuation
N/A
Accelerator
Alnylam Pharmaceuticals News
Alnylam Pharmaceuticals Inc. Arrowhead Pharmaceuticals Inc. Arbutus Biopharma Corporation; Benitec Biopharma Ltd. Sirnaomics, Ltd. For more...
Alnylam's commercial RNAi therapeutic products are ONPATTRO® (patisiran), GIVLAARI® (givosiran), OXLUMO® (lumasiran) and Leqvio® (inclisiran)...
We think that Alnylam Pharmaceuticals stock (NASDAQ: ALNY), a pharmaceutical company focused on RNA interference therapeutics for...
Alnylam Pharmaceuticals, Inc. (ALNY), the leading RNAi therapeutics company and Ironwood Pharmaceuticals, Inc. (IRWD), a GI healthcare ...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $297.7M | 2813 | -2% | N/A |
#2 | $300M | 2872 | 9% | N/A |
#3 | $1456.7M | 3153 | -4% | N/A |
#4 | $300M | 3226 | 9% | N/A |
#5 | N/A | 3340 | 52% | N/A |
Alnylam Pharmaceuticals Funding
Date | Amount | Round | Lead Investors | Reference |
---|---|---|---|---|
2002-08-02 | $15.0M | B | Article | |
2003-07-09 | $24.6M | Lead Investor: Multi | Article | |
2003-09-10 | $Undisclosed | Strategic Investmen | Merck | Article |
2006-12-18 | $101.0M | Undisclosed | America Securities LLC | Article |
2012-02-17 | $86.9M | Undisclosed | Article | |
2013-01-16 | $125.0M | Undisclosed | JP Morgan Securities LLC, Morgan Stanley & Co LLC | Article |
2013-01-18 | $173.8M | Undisclosed | Article | |
2014-01-14 | $700.0M | Undisclosed | Genzyme | Article |
2015-01-22 | $517.5M | Undisclosed | J.P. Morgan Securities LLC | Article |
2017-05-25 | $413.2M | Undisclosed | Barclays Capital Inc | Article |
2017-11-14 | $675.0M | Undisclosed | Goldman Sachs & Co. LLC | Article |
2019-01-16 | $445.6M | Undisclosed | Barclays Capital Inc | Article |